AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC

Key Points

• HSBC Holdings increased its AnaptysBio stake by 72.6% in the second quarter, adding 91,232 shares to own 216,949 shares valued at approximately $14.9 million, or 0.73% of the company.
• Several other institutional investors also expanded their positions, including Royal Bank of Canada and Caitong International Asset Management, though their holdings remain relatively small.
• AnaptysBio shares opened at $56.60, well below the 52-week high of $72.36. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $79.85.

Hsbc Holdings PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 72.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 216,949 shares of the biotechnology company's stock after purchasing an additional 91,232 shares during the period. Hsbc Holdings PLC owned about 0.73% of AnaptysBio worth $14,928,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd acquired a new position in AnaptysBio in the second quarter valued at approximately $39,000. Smartleaf Asset Management LLC increased its holdings in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock valued at $40,000 after buying an additional 821 shares in the last quarter. Larson Financial Group LLC raised its position in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 473 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company's stock worth $74,000 after acquiring an additional 1,383 shares during the period. Finally, Royal Bank of Canada boosted its stake in shares of AnaptysBio by 987.3% during the 4th quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company's stock worth $83,000 after acquiring an additional 1,560 shares in the last quarter.

AnaptysBio Stock Down 0.4%

AnaptysBio stock opened at $56.60 on Wednesday. AnaptysBio, Inc. has a 52-week low of $11.40 and a 52-week high of $72.36. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -52.41 and a beta of 0.71. The company has a fifty day simple moving average of $57.78 and a 200-day simple moving average of $59.27.

Analyst Upgrades and Downgrades

ANAB has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $95.00 price target on shares of AnaptysBio in a research report on Monday, August 24th. UBS Group boosted their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Wolfe Research reaffirmed an "outperform" rating and set a $78.00 target price on shares of AnaptysBio in a research note on Monday, August 31st. Barclays increased their target price on AnaptysBio from $63.00 to $75.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. Finally, Scotiabank cut shares of AnaptysBio to a "hold" rating and set a $70.00 price target on the stock. in a research note on Tuesday, August 25th. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $79.85.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.